Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial+Estimate
Composite+Estimate
500+Stocks+Estimate
Gold
Crude+Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
42.00
-0.92 (-2.14%)
Official Closing Price
Updated: 4:10 PM EDT, Jun 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,288,978
Open
42.72
Bid (Size)
42.00 (800)
Ask (Size)
42.03 (1,000)
Prev. Close
42.92
Today's Range
41.90 - 42.77
52wk Range
35.12 - 81.44
Shares Outstanding
N/A
Dividend Yield
6.07%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better
↗
Today 15:09 EDT
Can any company pose a serious challenge to Eli Lilly in the weight-loss market?
Via
The Motley Fool
Here's What I Think Is Really Going on With Novo Nordisk Stock
↗
Today 15:05 EDT
There is light at the end of the tunnel.
Via
The Motley Fool
Performance
YTD
-19.8%
-19.8%
1 Month
-5.4%
-5.4%
3 Month
+14.6%
+14.6%
6 Month
-11.4%
-11.4%
1 Year
-42.3%
-42.3%
More News
Read More
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
↗
Today 7:09 EDT
Via
The Motley Fool
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage
↗
June 02, 2026
Via
MarketBeat
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
↗
June 02, 2026
Via
The Motley Fool
Lexicon (LXRX) Q1 2026 Earnings Transcript
↗
June 01, 2026
Via
The Motley Fool
Is Eli Lilly Starting an Nvidia-Style Run?
↗
June 01, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
5 Best Growth Stocks for the Next 10 Years
↗
May 31, 2026
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
↗
May 30, 2026
Via
The Motley Fool
The Smartest Growth Stocks to Buy With $2,000 Right Now
↗
May 30, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Stock Split Watch: Is Eli Lilly Next?
↗
May 30, 2026
Via
The Motley Fool
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
↗
May 28, 2026
Via
The Motley Fool
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?
↗
May 28, 2026
Via
MarketBeat
Topics
Earnings
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?
↗
May 27, 2026
Via
The Motley Fool
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
↗
May 27, 2026
Via
The Motley Fool
Topics
Government
Prediction: These 2 Obesity Drug Stocks Could Double in 2026
↗
May 26, 2026
Via
The Motley Fool
Don't Buy Viking Therapeutics Stock Until You Read This
↗
May 25, 2026
Via
The Motley Fool
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
↗
May 25, 2026
Via
The Motley Fool
Topics
Intellectual Property
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
↗
May 25, 2026
Via
The Motley Fool
The Silver Lining of Last Week's Hims & Hers Earnings Miss
↗
May 21, 2026
Via
MarketBeat
Topics
Earnings
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
May 21, 2026
Via
FinancialNewsMedia
Topics
Government
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
May 21, 2026
From
MarketNewsUpdates.com
Via
GlobeNewswire
Could Viking Therapeutics Be the Next Eli Lilly?
↗
May 21, 2026
Via
The Motley Fool
Best Weight Loss Drug Stocks to Buy in 2026
↗
May 20, 2026
Via
The Motley Fool
Topics
Intellectual Property
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook
↗
May 20, 2026
Via
MarketBeat
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 42.00
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 06/03/26 04:10 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.